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The F-box protein Trcp1 controls the stability of several crucial regulators of proliferation and apoptosis,
including certain inhibitors of the NF-B family of transcription factors. Here we show that mammary glands
of Trcp1/ female mice display a hypoplastic phenotype, whereas no effects on cell proliferation are observed
in other somatic cells. To investigate further the role of Trcp1 in mammary gland development, we generated
transgenic mice expressing human Trcp1 targeted to epithelial cells under the control of the mouse mammary
tumor virus (MMTV) long terminal repeat promoter. Compared to controls, MMTV Trcp1 mammary glands
display an increase in lateral ductal branching and extensive arrays of alveolus-like protuberances. The
mammary epithelia of MMTV Trcp1 mice proliferate more and show increased NF-B DNA binding activity
and higher levels of nuclear NF-B p65/RelA. In addition, 38% of transgenic mice develop tumors, including
mammary, ovarian, and uterine carcinomas. The targeting of Trcp1 to lymphoid organs produces no effects
on these tissues. In summary, our results support the notion that Trcp1 positively controls the proliferation
of breast epithelium and indicate that alteration of Trcp1 function and expression may contribute to
malignant behavior of breast tumors, at least in part through NF-B transactivation.
F-box proteins (FBPs) are defined by the presence of an
approximately 40-amino-acid domain named the F box after
the protein, cyclin F, in which it was originally identified (2).
Studies in different species have shown that FBPs play a
crucial role in the ubiquitin-mediated degradation of cellu-
lar regulatory proteins (e.g., cyclins, cyclin-dependent ki-
nase inhibitors, -catenin, IB, etc.) (reviewed in references
11, 29, and 31). Indeed, FBPs are subunits of ubiquitin
ligases named SCFs because they comprise Skp1, Cul1, and
one of many FBPs.
Trcp1 (-transducin repeat-containing protein), the mam-
malian ortholog of Xenopus TrCP (53), was identified by
using either Skp1 or the pseudosubstrate Vpu as bait in two-
hybrid screens (13, 41). Mammalian Trcp1 and the paralo-
gous protein Trcp2 have been reported to be involved in
the degradation of IB (inhibitor of NF-B [nuclear factor
B]) family members in response to NF-B-activating stim-
uli (17, 21, 24, 25, 32, 45, 49, 52, 59–61). Several studies have
reported that Trcp1 and Trcp2 also control -catenin
stability in mammalian cultured cells (23, 24, 30, 37, 43, 59).
Furthermore, additional Trcp substrates have been pro-
posed: Atf4/Creb2 (35), Smad3 (18), Smad4 (57), the alpha
interferon receptor (33), the prolactin receptor (38), and the
disks large tumor suppressor (40). More recently, Trcp1
and Trcp2 have been implicated in cell cycle control. Dur-
ing the S and G2 phases, these two FBPs keep Cdk1 inactive
by inducing the degradation of its activating phosphatase
Cdc25a (9, 28). At the G2/M transition, Trcp1 and Trcp2
change their specificity by targeting the Cdk1-inactivating
kinase Wee1 for degradation (58), resulting in Cdc25a ac-
cumulation and Cdk1 activation. Finally, in mitosis Trcp1
and Trcp2 promote the degradation of Emi1 (22, 42, 47),
an inhibitor of the anaphase-promoting complex/cyclosome,
thereby attenuating Cdk1 activity via the anaphase-promot-
ing complex/cyclosome-mediated degradation of two acti-
vating cyclin subunits (cyclin A and cyclin B). Thus, Trcp1
and Trcp2 contribute to “turning off” Cdk1 in the S and G2
phases, turning it on at the G2/M transition, and turning it
off again in late mitosis.
Previously, we have shown that Trcp1 loss of function in
mice does not affect viability but induces an impairment of
spermatogenesis and reduced male fertility (22). In the
present study, we show that mammary glands of Trcp1/
mice display a hypoplastic phenotype. To investigate further
the role of Trcp1 in mammary gland development, we
generated and characterized a transgenic mouse model in
which we targeted Trcp1 expression to epithelial cells us-
ing the mouse mammary tumor virus (MMTV) promoter. In
addition, the epithelial-tissue-specific phenotype observed
in both the loss-of-function and gain-of-function mouse
models was confirmed by generating a transgenic mouse
mutant in which Trcp1 expression was targeted to the
lymphoid organs using the CD4 promoter and in which no
phenotype was observed. The results of these studies are
herein presented.
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MATERIALS AND METHODS
Generation of MMTV Trcp1 and CD4 Trcp1 transgenic mice. The MMTV
Trcp1 transgene construct was generated by cloning the human Trcp1 cDNA
into the pMSG expression vector that contains an MMTV long terminal repeat
promoter and a simian virus 40 polyadenylation signal (15, 56). The CD4 Trcp1
transgene construct was generated by cloning the human Trcp1 cDNA in a
plasmid containing the minimal CD4 enhancer, the minimal murine CD4 pro-
moter, the transcriptional initiation site, and 70 bp of the untranslated first exon
and part of the first intron of the murine CD4 gene (36). Constructs were
injected into the pronuclei of fertilized eggs from B6D2F1 donors, which were
subsequently transferred into pseudopregnant mice. The strain was maintained
on a BALB/c genetic background. Screening of founder animals and their off-
spring was performed by genomic PCR and confirmed by Southern hybridization
on genomic DNA from tail biopsy samples. The following primers were used for
genomic PCR: 5-CTGGCTATCATCACAAGAGCGGAACGGA-3 and 5-C
CCAAGCTTCTTCCACAGCATGCCGTCA-3.
RNA extraction and reverse transcription-PCR (RT-PCR) analysis. Total
RNA was extracted using RNeasy (QIAGEN) according to the manufacturer’s
instructions. RNA was quantified, and its purity was determined by standard
spectrophotometric methods. cDNA was synthesized from 1 g of the total RNA
by using the Omniscript RT kit (QIAGEN). The following primers specific to
human Trcp1 were used: F, 5-AATTCCTCAGAGAGAGAAGACT-3, and
R, 5-TCTGGCAAAACACTAAATATAT-3. To amplify mouse GAPDH, the
following primers were used: F, 5-GGGTGGAGCCAAACGGGTC-3, and R,
5-GGAGTTGCTGTTGAAGTCGCA-3. cDNA was amplified using 1 U of Taq
DNA polymerase (Fermentas Inc., Hanover, Md.), and amplification was performed
in a PTC-100 thermal cycler (MJ Research Inc.) for 35 cycles (denaturation at 94°C
for 1 min, annealing for 1 min, and extension at 72°C for 2 min). The annealing
temperatures were as follows: for human Trcp1, 55°C; for mouse GAPDH, 58°C.
The amplification reaction products were resolved on 2.0% agarose–Tris-acetate-
EDTA gels, electrophoresed at 100 V, and visualized by ethidium bromide staining.
Histology and whole-mount preparation. The animals were monitored daily.
Necropsies were performed on all animals that died spontaneously during the
observation period. For histological analysis, mammary glands and other tissues
were fixed overnight or longer in 10% phosphate-buffered formalin, embedded in
paraffin, and sectioned. They were stained with hematoxylin and eosin for his-
tological analysis. For whole-mount tissue preparations, mammary glands were
processed as described previously (27).
Immunohistochemistry and bromodeoxyuridine (BrdU) incorporation. For
immunohistochemical staining, deparaffinized sections were immersed in meth-
anol containing 0.03% hydrogen peroxide for 30 min to block endogenous per-
oxidase activity. The slides were subjected to microwaving in 10 mM citrate
buffer three times for 5 min and then incubated with Protein Block Serum-Free
(Dako, Tucson, Ariz.) for 30 min to block the nonspecific antibody binding sites.
The slides were treated with an anti-p65/RelA polyclonal antibody (1:100; Santa
Cruz) at 4°C overnight and then with EnVision (Dako) for 30 min. Peroxidase
activity was developed using 3,3-diaminobenzidine tetrahydrochloride in 50 mM
Tris-HCl (pH 7.5) containing 0.001% hydrogen peroxidase. The sections were
slightly counterstained with Mayer’s hematoxylin. For the negative control, the
primary antibodies were replaced with normal mouse serum.
For BrdU incorporation, a sterile solution containing 10 mg of BrdU (Sig-
ma)/ml and 0.6 mg of fluorodeoxyuridine (Sigma)/ml in phosphate-buffered
saline was injected intraperitoneally (100 l/10 g of body weight). After 2 h, the
mice were sacrificed, mammary glands were collected and fixed, and 5-m
sections were prepared. BrdU incorporation was visualized by immunohisto-
chemistry using a BrdU detection kit (Zymed Laboratories), and the nuclei were
counterstained with hematoxylin. For quantification, 10 random fields per sec-
tion at a magnification of 40 were documented by photomicroscopy, and the
percentage of BrdU-positive epithelial-cell nuclei relative to the total number of
epithelial-cell nuclei was calculated.
Electrophoretic mobility shift assay. The electrophoretic mobility shift assay
was performed as described previously (4, 46). Briefly, 3 l (approximately 3 g)
of cell extract was incubated for 20 min at room temperature in 20 l of buffer
(20 mM Tris [ph 7.4], 5% glycerol, 0.1% Tween 20, 0.5 mM MgCl2, 1 mM
dithiothreitol, 1 mM EDTA, 50 mM KCl) containing 2 g of poly(dI-dC) and a
B probe (100,000 cpm) labeled using Klenow fill-in. The probe was the palin-
dromic B probe previously described (6). The mixture was then separated on a
native polyacrylamide gel that was dried and exposed for autoradiography.
Immunoblotting and Northern blotting. Immunoblotting and Northern blot-
ting were performed as previously described (12, 22). Antibodies to cyclin A (3),
Emi1, -catenin, and IB (22) were previously described. Antibodies to IB,
NF-B1/p105, and keratin 18 were from Santa Cruz Biotechnology, antibody to
c-Myc was from Sigma, and antibody to cyclin D1 was from Zymed.
RESULTS
Hypoplastic phenotype of Trcp1/ mammary gland. To
study the function of Trcp1 in the development of the mam-
mary gland, we analyzed whole-mount preparations of mam-
mary glands from wild-type and Trcp1-deficient female virgin
mice. In comparison with those of wild-type mice, mammary
glands from Trcp1/ mice showed a hypobranching pheno-
type (Fig. 1a, b, d, and e). Histological examination confirmed
the hypoplasia of Trcp1/ mammary glands (Fig. 1c and f).
In virgin adults (approximately 6 months of age), this pheno-
type was highly penetrant (found in 9 of 10 mice). In contrast,
no significant differences between the two phenotypes were
observed during pubertal ductal elongation, pregnancy, and
lactation, the times of maximal hormonal stimulation.
To determine whether the observed defects in mammary
gland development were the result of reduced cell prolifera-
tion, DNA synthesis was measured in an in vivo BrdU incor-
poration assay. Six-month-old virgin mice were administered
BrdU, whose incorporation into DNA was then detected by
immunohistochemistry (Fig. 1g). In Trcp1/ mammary
glands, the proliferation index, calculated as the percentage of
BrdU-positive cells out of the total epithelial cells, was approx-
imately 50% of that measured in estrus-matched wild-type
mice (5.6% 	 1.9% versus 9.9% 	 2.2%; P 
 0.001). In con-
trast, no differences in BrdU incorporation were detected in
other organs, such as intestine and skin (Fig. 1g). Apoptosis,
measured as the percentage of cells positive by terminal de-
oxynucleotidyltransferase-mediated dUTP-biotin nick end la-
beling (TUNEL), at different ages was not different between
the two genotypes (data not shown). The presence of a hyper-
plastic phenotype in the mammary glands of Trcp1/ mice
was not the result of a lack of Trcp2 expression in mammary
epithelial cells, as shown by Northern blot analysis (Fig. 1h).
Thus, we conclude that Trcp1 is necessary for the proper
development of the mouse mammary gland under conditions
of low hormonal stimuli.
Targeted expression of Trcp1 induces hyperplasia and
transformation in epithelial organs. To further analyze the
role of Trcp1 in the development of the mammary gland
epithelium, we generated Trcp1 transgenic mice by placing
the human Trcp1 cDNA under the control of the MMTV
long terminal repeat promoter (Fig. 2A to C). Using this con-
struct, three independent Trcp1 transgenic lines of mice were
obtained, but all the experiments described herein were per-
formed with two MMTV Trcp1 transgenic lines (lines 2 and
19) that expressed similar Trcp1 levels in the breast epithe-
lium (Fig. 2A).
MMTV Trcp1 mice appeared normal at birth, and their
growth was indistinguishable from that of their wild-type lit-
termates. Compared to those of wild-type virgin female mice,
the mammary glands of MMTV Trcp1 mice (six mice, ap-
proximately 10 weeks of age, for each genotype) were found by
whole-mount analysis to display an increase in lateral ductal
branching and extensive arrays of alveolus-like hyperplasia
(Fig. 3A, panels a and d). At a higher magnification, the ducts
were shorter, wider, and covered with small alveolus-like pro-
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FIG. 1. Mammary gland hypoplasia in Trcp1/ mice. (a to f) Whole-mount preparations (a, b, d, and e) and hematoxylin and eosin-stained
sections (c and f) of inguinal mammary glands from 6-month-old virgin Trcp1/ mice (d to f) and wild-type littermates (a to c). LN, lymph node.
(g) BrdU incorporation in the indicated organs of virgin Trcp1/ mice and wild-type littermates. The percentages of BrdU-positive nuclei were
calculated. Error bars represent standard errors of the means. (h) Levels of Trcp1 and Trcp2 mRNAs in mammary epithelial cells (MECs) and
mouse embryonic fibroblasts (MEFs).
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tuberances (Fig. 3A, panels b and e). In histological sections
the number of ducts was increased in comparison to wild-type
glands. In addition, the ductal epithelial-cell layers of MMTV
Trcp1 glands were thicker than those from wild-type mice
(Fig. 3A, panels c and f), confirming the pervasive ductal hy-
perplasia. The observed hyperplasia of the mammary gland
correlated with a twofold increase in cell proliferation, as mea-
sured by an in vivo BrdU incorporation assay (28.1% 	 5.2%
versus 14.4% 	 2.9%; P 
 0.016) (Fig. 3A, panel g). In con-
trast, apoptosis, measured as the percentage of TUNEL-posi-
tive cells, was not significantly different in either virgin (data
not shown) or breeder transgenic mice during mammary invo-
lution (Fig. 3A, panel h), although it appeared somehow de-
layed (values at day 10 for transgenic mice were similar to
values at day 5 for wild-type animals, and vice versa).
The aberrant hyperplasia of mammary glands of Trcp1
transgenic mice was maintained throughout life. In older ani-
mals (14 to 22 months of age), the difference with the controls
was dramatic (Fig. 3B, panels a to f). This mammary-gland
hyperplasia was observed in 8 out of 10 virgin aged Trcp1
transgenic mice examined, but not in wild-type virgin aged
mice (0 out of 8). In addition, malignant transformation of the
mammary gland was observed in two Trcp1 transgenic ani-
mals (n 
 47) but was never observed in the control mice (n 

43). Histopathological analysis indicated that these two mam-
mary tumors were adenocarcinomas, one showing both a tu-
bular pattern (well-formed duct-like structures) and a papillary
pattern and the other displaying a solid tubular pattern (Fig.
4A). Overall, 38% of MMTV Trcp1 females developed epi-
thelial tumors, including mammary, ovarian, and uterine tu-
mors, at an incidence significantly higher than that in wild-type
mice (Fig. 4B and D). The presence of tumors in other epi-
thelial tissues is not surprising since the MMTV promoter
targets Trcp1 expression not only to the mammary gland but
also to uterine, ovarian, and other epithelial cells, such as those
of the salivary glands, lachrymal glands, and lung (Fig. 2B).
These results suggest that targeted expression of Trcp1
induces hyperplasia and transformation in epithelial organs,
particularly those devoted to reproduction and lactation. To
confirm this specificity, we generated transgenic mice express-
ing Trcp1 targeted to the T-lymphoid lineage by using the
murine CD4 promoter to drive the expression in thymic T cells
(Fig. 2D). Despite a Trcp1 expression similar to that achieved
in breast cells, no difference in cell proliferation (data not
shown) and tumor incidence (Fig. 4C) was observed between
CD4 transgenic mice and controls.
Trcp1 activates NF-B in breast epithelium. Trcp1 me-
diates the ubiquitination of several cellular substrates including
IB family members (i.e., IB, IB, and IBε) resulting in
their proteasome-dependent degradation and consequent ac-
FIG. 2. Characterization of MMTV Trcp1 and CD4 Trcp1 transgene expressions. (A) RT-PCR analysis of the Trcp1 transgene expression
in mammary glands. RT-PCR was performed with primers specific to human Trcp1 or to mouse GAPDH; 1 g of total RNA prepared from
mammary glands of the indicated lines of 10-week-old (10W) and 25-month-old (25M) transgenic (TG) and wild-type (WT) virgin mice.
(B) RT-PCR analysis of MMTV Trcp1 transgene expression in the indicated organs. (C) RT-PCR analysis of transgene expression in mammary
glands of 10W virgin mice or during pregnancy (Preg), lactation (Lac), or involution (Inv) at different days (d). (D) RT-PCR analysis of the
CD4-Trcp1 transgene expression in thymus and mammary gland.
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FIG. 3. Mammary gland hyperplasia in MMTV Trcp1 transgenic mice. (A) Whole mounts (a, b, d, and e) and hematoxylin and eosin-stained
sections (c and f) of inguinal mammary glands from 10-week-old virgin MMTV Trcp1 transgenic mice (d to f) and wild-type (WT) littermates
(a to c). LN, lymph node. (g) BrdU incorporation in breast epithelium of 10-week-old virgin WT and estrus-matched MMTV Trcp1 transgenic
littermates. The percentages of BrdU-positive nuclei were calculated. (h) Percentages of TUNEL-positive nuclei at different days after removal
of pups. Error bars represent standard errors of the means. (B) Whole mounts (a, b, d, and e) and hematoxylin and eosin-stained (c and f) sections
of inguinal mammary glands from 22-month-old WT mice (a to c) and MMTV Trcp1 transgenic littermates (d to f).
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tivation of the NF-B transcription activity. To determine
whether Trcp1 expression in mammary glands was associated
with an increased activation of NF-B, we examined the DNA
binding activity of NF-B in the mammary, lachrymal, and
salivary glands, in the uterus, and in the ovary. Mammary
gland, ovary, and uterus of 10-week-old virgin transgenic fe-
males showed higher NF-B activity in comparison with that of
wild-type females (Fig. 5A and data not shown). This increase
was also evident in mammary glands of older mice (6 and 22
months old) and in breast tumors in MMTV Trcp1 transgenic
mice (Fig. 5A, panel b).
As an independent way to test the status of the NF-B
pathway (7), we examined by immunohistochemistry the nu-
clear localization of p65/RelA, which increases in response to
NF-B activation. The nuclear localization of p65/RelA in
mammary epithelial cells of 10-week-old MMTV Trcp1 trans-
genic mice was much higher than that in wild-type animals
(Fig. 5B).
Lastly, we analyzed by immunoblotting the expression of cell
cycle regulatory proteins and members of the NF-B and
-catenin pathways in mammary glands from 10-week-old vir-
gin wild-type and Trcp1 transgenic mice (Fig. 5C). In 75% of
the cases (eight mice for each genotype), we observed a sig-
nificant increase in the levels of cyclin D1 in mammary glands
from Trcp1 transgenic mice compared with those in wild-type
glands. In contrast, the levels of IB, IB, NF-B1/p105,
NF-B2/p100, -catenin, cyclin A, Emi1, Wee1, and c-Myc
were identical in wild-type and Trcp1 transgenic mammary
glands (Fig. 5C and data not shown).
DISCUSSION
A Trcp1-deficient mouse mutant was previously generated,
and what at that time was an unsuspected role for Trcp1 in
controlling both meiosis and mitosis was found (22). In the
present study, we have found that in the absence of elevated
hormonal stimuli, loss of Trcp1 induces a hypoplastic pheno-
type in mammary glands (Fig. 1). In addition, cell proliferation
is decreased in breast epithelium but not in other organs, such
as skin and intestine (Fig. 1). Similarly, we were unable to find
alterations in the lymphoid compartments of Trcp1/ mice.
We investigated the development of T and B cells and exten-
sively tested for the presence of alterations in the immune
response and defects in the apoptotic response without finding
FIG. 3—Continued.
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any significant difference between mutant and wild-type mice
(data not shown). Accordingly, we did not observe any aber-
rant response of thymocytes and macrophages of Trcp1/
mice to a variety of stimuli or stresses (22).
To confirm a role for Trcp1 in the development of the
mammary gland, we generated an MMTV Trcp1 transgenic
mouse mutant (Fig. 2A). We found that targeting expression of
Trcp1 to the mammary gland enhances proliferation and
induces hyperbranching and hyperplastic nodules (Fig. 3A), a
phenotype exactly opposite to that observed in the loss-of-
function model. The phenotype observed in MMTV Trcp1
mice is most evident in aged animals, in which mammary hy-
perplasia is observed in 80% of cases (Fig. 3B). Moreover, 38%
of MMTV Trcp1 mice developed tumors (Fig. 4D) localized
to the breast, ovary, uterus, and lung, all organs in which the
MMTV promoter induces Trcp1 expression (Fig. 2B). In
contrast, targeting Trcp1 expression to lymphoid organs using
the T-cell-specific promoter CD4 did not produce any effect on
either cell proliferation (data not shown) or tumor develop-
ment (Fig. 4C).
NF-B is the generic term for a family of transcription fac-
tors that regulates key genes involved in cell proliferation,
apoptosis, immune responses, and inflammation (19). NF-B
is activated by a wide variety of different stimuli, including
proinflammatory cytokines such as tumor necrosis factor alpha
FIG. 4. Trcp1 expression induces tumorigenesis in epithelial or-
gans. (A) Hematoxylin and eosin-stained section of two mammary
adenocarcinomas found in MMTV Trcp1 mice, one with a papillo-
tubular pattern (a) and the other displaying a solid tubular pattern (b).
(B) Graph of tumor incidence in MMTV Trcp1 transgenic mice and
control wild-type littermates. The percentage of animals in each cohort
remaining free of palpable tumors was plotted as a function of age for
Trcp1 transgenic mice (n 
 47) and wild-type mice (n 
 43).
(C) Graph of tumor incidence in CD4 Trcp1 transgenic mice and
control wild-type littermates. The percentage of animals in each cohort
remaining free of palpable tumors was plotted as a function of age for
Trcp1 transgenic mice (n 
 49) and wild-type mice (n 
 20). (D) Ta-
ble showing tumors arising in MMTV Trcp1 mice (TG) and control
littermates (WT). There was no significant difference in the develop-
ment of tumors between virgin and breeder MMTV Trcp1 females.
The difference between total number of tumors and total number of
mice in the TG column (indicated by an asterisk) is due to the presence
of two tumors found in the same mouse.
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FIG. 5. NF-B activity is increased in MMTV Trcp1 transgenic mice. (A) DNA binding activity of NF-B in mammary gland (MG), lachrymal
gland (LG), salivary gland (SG), and uterine horn (U) (a). NF-B activity during the development of mammary gland (virgin mice at 10 weeks and
6 and 22 months of age) and in a breast tumor (MG tumor) in an MMTV Trcp1 transgenic mouse (b). (B) Nuclear expression of p65/RelA in
mammary glands of 10-week-old wild-type and MMTV Trcp1 transgenic mice. Arrows show representative immunopositive cells with nuclear
staining. (C) Extracts from mammary glands of two representative 10-week-old wild-type (WT) and two Trcp1 transgenic (TG) mice were
subjected to immunoblotting with the indicated antibodies (keratin 18 is shown as a control for the epithelial content of the sample).
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and interleukin-1, bacteria, and bacterial lipopolysaccharide,
viruses, viral proteins, double-stranded RNA, and physical and
chemical stresses. After stimulation, the IB kinase, IKK, me-
diates phosphorylation of IB on two critical serine residues,
leading to the immediate recognition by Trcp and consequent
polyubiquitinylation of IB via the SCFTrcp complex (21, 24,
25, 32, 45, 49, 52, 59–61). The consequent rapid degradation of
IB by the 26S proteasome exposes the nuclear localization
sequence of NF-B family members (e.g., p50 and p65/RelA),
resulting in their translocation to the nucleus, where they in-
duce the transcription of target genes. NF-B1/p105 functions
both as a precursor of NF-B/p50 and as a cytoplasmic inhib-
itor of NF-B, and its degradation is also mediated by Trcp
(26, 34).
We found that the increase in cell proliferation observed in
MMTV Trcp1 mice associates with an activation of the
NF-B pathway determined by measuring both B DNA bind-
ing activity and the abundance of nuclear p65/RelA (Fig. 5A
and B). The positive regulation of NF-B activity by Trcp1 is
likely to represent one of the reasons for the changes in cell
proliferation observed in the mammary glands of our mouse
models. Consistent with this hypothesis, an increase or a de-
crease in BrdU incorporation was observed in breast epithe-
lium lacking IB (7) or expressing an inactive IKK (10),
respectively. These two former studies also agree with ours on
another issue: in all three cases, no significant differences in
apoptosis rates were observed in mammary glands upon
NF-B activation, despite the well-established role of this tran-
scription factor in inhibiting apoptosis. Since NF-B is partic-
ularly activated during pregnancy, peaking around days 15 to
16 post coitum and during involution, it is possible that a
further increase in activity is not achievable because of a pla-
teau. Finally, the work by Cao and colleagues shows that cyclin
D1 is a critical effector of the network that controls mammary
epithelial proliferation in response to NF-B activation (10).
Similarly, we found elevated levels of cyclin D1 in mammary
glands of Trcp1 transgenic mice (Fig. 5C), which display high
NF-B activity.
NF-B activation not only plays an important role in the
development of the mouse mammary gland (7, 8, 10), but it is
also known as a key player in oncogenesis, promoting prolif-
eration and inhibiting apoptosis (reviewed in reference 39).
Elevated and/or constitutive NF-B activation is found in a
variety of tumors (20), including breast cancers (14, 44, 50, 51).
In addition, transgenic mice overexpressing the NF-B family
member c-Rel in breast epithelium develop late-onset mam-
mary carcinomas (48). Our data confirm and extend this notion
by showing a role for Trcp1, an activator of NF-B, in con-
trolling proliferation of breast epithelial cells and in contrib-
uting to their transformation. Given the well-established role
of cyclin D1 in the growth control and transformation of breast
epithelium, it is possible that the effect of Trcp1 on breast
tumorigenesis is, at least in part, mediated by the increase in
cyclin D1 levels (Fig. 5C). In agreement with our studies of
breast tumors, Trcp1 has been found to be overexpressed in
human colorectal carcinomas, and Wnt signaling induces the
expression of Trcp1 in colon cancer cell lines with a conse-
quent upregulation of NF-B transactivation (54). Further-
more, Trcp2 is upregulated in tumor cell lines (including
breast cancer lines) (55) and in chemically induced mouse
papillomas and squamous-cell carcinomas, and this overex-
pression is associated with constitutive activation of NF-B (5).
How does Trcp1 activate NFB in the MMTV Trcp1
mice? Are other substrates affected by the lack or overexpres-
sion of Trcp1 in breast and other epithelial cells? The
SCFTrcp complex targets several substrates for degradation,
including IB family members, NF-B1/p105, -catenin, Emi1,
Cdc25a, Wee1, Atf4/Creb2, Smad3/4, the alpha interferon re-
ceptor, the prolactin receptor, and the disks large tumor sup-
pressor. In addition, Trcp1 activates NF-B by inducing the
processing of NF-B2/p100 (1, 16). We could not observe in
MMTV Trcp1 or Trcp1/ mice any significant changes in
the levels of Trcp1 substrates by either immunoblotting (for
IB, IB, NF-B1/p105, NF-B2/p100, -catenin, Emi1,
and Wee1) or immunohistochemistry (-catenin) (Fig. 5C and
data not shown). However, we could observe a clear effect on
NF-B activation. A possible explanation for the lack of
changes in Trcp1-deficient mice is the redundancy with
Trcp2, which is well expressed in breast epithelial cells (Fig.
1h). In transgenic animals the explanation is more difficult;
however, it needs to be reiterated that while on one hand
Trcp induces IB degradation, on the other, by activating
NF-B, it induces the synthesis of IB, obscuring IB pro-
teolysis. In addition, it is possible that levels of endogenous
Trcp1 are limiting and that the forced expression of Trcp1
induces small perturbations in the degradation of IB, IB,
IBε, and NF-B1/p105 and in the processing of NF-B2/p100,
the sum of which produces, as a final result, a prolonged and
enhanced activation of NF-B.
So far, of more than 70 human FBPs, only 4 have been well
characterized and matched to downstream substrates: Trcp1,
Trcp2, Skp2, and Fbw7. Of these, Skp2 is the product of a
protooncogene, while Fbw7 is a tumor suppressor protein. The
results herein demonstrate a role for Trcp1 in the develop-
ment of the mammary gland. Furthermore, our results indicate
that Trcp1 might contribute to the malignant behavior of
breast and other epithelial cells by providing a gain of function,
at least in part via the overactivation of NF-B.
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